The big money: Poised to make drug R&D history, a China biotech unveils unicorn racing ambitions in a bid to raise $350M-plus on Nasdaq

John Carroll

Editor & Founder

Almost exactly three years after Shanghai-based Legend came out of nowhere to steal the show at ASCO with jaw-dropping data on their BCMA-targeted CAR …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The big money: Poised to make drug R&D history, a China biotech unveils unicorn racing ambitions in a bid to raise $350M-plus on Nasdaq

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Trump 2.0 blog: Wayback Machine is insufficient for US health data, judge says

Travere plans to seek expanded label for kidney drug despite failed trial

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Biohaven lands priority review on second-chance application for neurodegenerative drug

What will pharma's share buyback shopping spree mean for M&A?

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

The big mon­ey: Poised to make drug R&D his­to­ry, a Chi­na biotech un­veils uni­corn rac­ing am­bi­tions in a bid to raise $350M-plus on Nas­daq

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

The big money: Poised to make drug R&D history, a China biotech unveils unicorn racing ambitions in a bid to raise $350M-plus on Nasdaq